乳腺癌患者内分泌治疗相关症状的调查研究

doi:10.3761/j.issn.0254-1769.2021.05.016

摘要/Abstract

摘要：

目的调查乳腺癌患者内分泌治疗相关症状的发生情况,并探讨其影响因素。方法采用方便抽样方法,应用一般情况调查表、乳腺癌内分泌治疗知识和态度问卷、乳腺癌患者生命质量测定-内分泌症状量表,于2019年11月—2020年4月在上海市2所三级甲等医院及1所抗癌康复俱乐部的患者随访平台对正在接受内分泌治疗的乳腺癌患者进行在线调查。结果共回收有效问卷613份,患者内分泌症状量表评分总分为（18.99±11.43）分,其中容易烦躁或易怒、情绪波动、对性生活失去兴趣、潮热、关节痛、性交疼痛或不适是发生率和严重程度较高的症状。多元线性回归结果显示,年龄、自费、内分泌治疗药物种类、既往手术、既往化疗、内分泌治疗态度是症状发生的独立影响因素（P<0.05）,可解释总变异的19.1%。结论乳腺癌患者内分泌治疗相关症状的发生率高,症状负担重,年龄小、自费、使用选择性雌激素受体调节剂、既往手术、既往化疗、内分泌治疗态度差的患者症状负担更重。

关键词: 乳腺肿瘤, 内分泌治疗, 症状, 影响因素分析, 护理

Abstract:

Objective To describe the occurrence and risk factors of symptoms among breast cancer survivors undergoing adjuvant endocrine therapy.Methods Breast cancer patients undergoing adjuvant endocrine therapy were investigated online with convenience sampling by the general information questionnaire,knowledge and attitude questionnaire and Functional Assessment of Cancer Therapy-Endocrine Subscale during November 2019 to April 2020 in A level A tertiary hospitals in Shanghai,and the Shanghai Anticancer Rehabilitation Club.Results The total symptoms score of 613 breast cancer survivors undergoing adjuvant endocrine therapy was 18.99±11.43,among which irritable,mood swings,lost interest in sex,hot flashes,joint pain,pain or discomfort with intercourse are symptoms with a higher incidence and severity. The multivariate linear regression analysis showed that age,self-payment,types of endocrine therapy drugs,previous surgery,previous chemotherapy,attitude to endocrine therapy were the independent influencing factors of symptoms（P<0.05）,which accounted 19.1% of the total variation.Conclusion The incidence of adjuvant endocrine therapy-related symptoms in breast cancer patients is high,and the symptom burden is heavy. The patients with younger age,self-payment,the use of selective estrogen receptor modulator,previous surgery,previous chemotherapy,a poor attitude toward endocrine therapy tended to have a higher symptom burden.

Key words: Breast Neoplasms, Endocrine Therapy, Symptoms, Influencing Factors Analysis, Nursing Care

荆凤,邢唯杰,裘佳佳,汤立晨,徐蕾,胡雁. 乳腺癌患者内分泌治疗相关症状的调查研究[J]. 中华护理杂志, 2021, 56(5): 737-742.

JING Feng,XING Weijie,QIU Jiajia,TANG Lichen,XU Lei,HU Yan. Symptoms and its influencing factors among breast cancer survivors undergoing adjuvant endocrine therapy[J]. Chinese Journal of Nursing, 2021, 56(5): 737-742.

图/表 3

表1 研究对象的一般资料和内分泌治疗相关症状单因素分析结果（n=613）

Table 1 General information of the subjects and univariate analysis of symptoms associated with endocrine therapy（n=613）

表2 乳腺癌患者内分泌治疗相关症状发生情况（n=613）

Table 2 Incidence of symptoms associated with endocrine therapy for breast cancer（n=613）

表3 乳腺癌患者内分泌治疗相关症状影响因素的多元线性回归分析

Table 3 Multiple linear regression analysis of endocrine treatment-related symptoms of breast cancer

参考文献 26

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA:A Cancer J Clin, 2018,68(6):394-424. DOI URL
[2]	赵健洁, 张晓华, 郝帅, 等. 雌激素受体阳性乳腺癌内分泌治疗疗效预测标志物研究进展[J]. 重庆医科大学学报, 2019,44(12):1542-1546.
	Zhao JJ, Zhang XH, Hao S, et al. Progress in predictive markers of neoadjuvant endocrine therapy for ER+ breast cancer[J]. J Chongqing Med Univ, 2019,44(12):1542-1546.
[3]	李开春, 王雅杰. 激素受体阳性晚期乳腺癌内分泌治疗选择[J]. 肿瘤学杂志, 2020,26(1):7-12.
	Li KC, Wang YJ. Choice of endocrine therapy for advanced breast cancer with hormone receptor positive[J]. J Chin Oncol, 2020,26(1):7-12.
[4]	Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer:patient-level meta-analysis of the randomisedtrials[J]. Lancet, 2015,386(10001):1341-1352. DOI URL
[5]	Chan CWH, Tai D, Kwong S, et al. The effects of pharmacological and non-pharmacological interventions on symptom management and quality of life among breast cancer survivors undergoing adjuvant endocrine therapy:a systematic review[J]. Int J Environ Res Public Heal, 2020,17(8):2950.
[6]	Honma N, Makita M, Saji S, et al. Characteristics of adverse events of endocrine therapies among older patients with breast cancer[J]. Support Care Cancer, 2019,27(10):3813-3822. DOI URL
[7]	Ochayon L, Tunin RN, Yoselis A, et al. Symptoms of hormonal therapy and social support:is there a connection? Comparison of symptom severity,symptom interference and social support among breast cancer patients receiving and not receiving adjuvant hormonal treatment[J]. Eur J Oncol Nurs, 2015,19(3):260-267. DOI PMID
[8]	Sestak I, Cuzick J, Sapunar F, et al. Risk factors for joint symp-toms in patients enrolled in the ATAC trial:a retrospective,exploratory analysis[J]. Lancet Oncol, 2008,9(9):866-872. DOI URL
[9]	张静, 吴忠辉, 李佳, 等. 化疗期乳腺癌病人症状群及其影响因素调查研究[J]. 护理研究, 2017,31(32):4097-4102.
	Zhang J, Wu ZH, Li J, et al. Investigation on symptoms group and its influencing factors in patients with breastcancer during chemotherapy[J]. Nurs Res China, 2017,31(32):4097-4102.
[10]	黄青梅, 耿朝辉, 吴傅蕾, 等. 乳腺癌患者化疗期间症状群特征及预测指标的研究[J]. 中华护理杂志, 2020,55(9):1297-1303.
	Huang QM, Geng ZH, Wu FL, et al. Study on differential cha-racters of symptom clusters and predictors of breast cancer patients during chemotherapy[J]. Chin J Nurs, 2020,55(9):1297-1303.
[11]	朱叶卉, 胡雁, 吴密彬, 等. 电话随访对乳腺癌患者服药依从性和生活质量的影响[J]. 中华护理杂志, 2015,50(1):69-73.
	Zhu YH, Hu Y, Wu MB, et al. Effect of nurse-led follow-up on medication adherence and quality of life of patients with breast cancer[J]. Chin J Nurs, 2015,50(1):69-73.
[12]	王春青, 胡雁, 吴密彬, 等. 乳腺癌患者内分泌治疗服药监控平台的设计及应用[J]. 中华护理杂志, 2017,52(3):261-266.
	Wang CQ, Hu Y, Wu MB, et al. The effectiveness of computer-based monitoring system for patients with breast cancer receiving adjuvant hormonal therapy[J]. Chin J Nurs, 2017,52(3):261-266.
[13]	段晓磊, 徐燕, 朱大乔, 等. 癌症症状管理理论和实践的研究进展[J]. 中华护理杂志, 2013,48(6):564-566.
	Duan XL, Xu Y, Zhu DQ, et al. Advances in cancer symptom management theory and practice[J]. Chin J Nurs, 2013,48(6):564-566.
[14]	胡雁, 王志稳, 刘均娥, 等. 护理研究[M]. 5版. 北京: 人民卫生出版社, 2017: 360.
	Hu Y, Wang ZW, Liu JE, et al. Nursing research[M].version 5. Beijing: People’s Medical Publishing House, 2017: 360.
[15]	Fallowfield LJ, Leaity SK, Howell A, et al. Assessment of quality of life in women undergoing hormonal therapy for breast cancer:validation of an endocrine symptom subscale for the FACT-B[J]. Breast Cancer Res Treat, 1999,55(2):189-199.
[16]	李晴晴, 吴婉英. 乳腺癌病人内分泌治疗症状评估工具的研究进展[J]. 护理研究, 2020,34(19):3443-3448.
	Li QQ, Wu WY. Research progress on symptom assessment tools for endocrine therapy in breast cancer patients[J]. Chin Nurs Res, 2020,34(19):3443-3448.
[17]	刘诗盈, 王爱平, 金锋, 等. 乳腺癌病人内分泌治疗的副反应对生命质量的影响[J]. 护理研究, 2017,31(6):686-689.
	Liu SY, Wang AP, Jin F, et al. Influence of adverse reactions of endocrine therapy on quality of life of patients with breast cancer[J]. Nurs Res China, 2017,31(6):686-689.
[18]	Aiello Bowles EJ, Boudreau DM, Chubak J, et al. Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer[J]. J Oncol Pract, 2012,8(6):e149-e157. DOI URL
[19]	Zhu Y, Cohen SM, Rosenzweig MQ, et al. Symptom map of endocrine therapy for breast cancer:a scoping review[J]. Cancer Nurs, 2019,42(5):E19-E30. DOI URL
[20]	Berkowitz MJ, Thompson CK, Zibecchi LT, et al. How patients experience endocrine therapy for breast cancer:an online survey of side effects,adherence,and medical team support[J]. J Cancer Surviv, 2020: 1-11.
[21]	高碧丽, 丁玉兰, 沈良盛. 自我效能干预对乳腺癌内分泌治疗的影响[J]. 中国卫生标准管理, 2019,10(16):158-161.
	Gao BL, Ding YL, Shen LS. Effect of self-efficacy intervention on oral endocrine therapy for mammary cancer[J]. China Heal Stand Manag, 2019,10(16):158-161.
[22]	马飞, 徐兵河, 邵志敏. 乳腺癌随访及伴随疾病全方位管理指南[J]. 中华肿瘤杂志, 2019,41(1):29-41. DOI PMID
	Ma F, Xu BH, Shao ZM. Comprehensive management guideline for breast cancer follow up and concomitant diseases[J]. Chin J Oncol, 2019,41(1):29-41. DOI PMID
[23]	Wassermann J, Gelber SI, Rosenberg SM, et al. Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer[J]. Cancer, 2019,125(18):3266-3274. DOI PMID
[24]	景静凤, 高晋南, 李冬, 等. 乳腺癌经济毒性研究进展[J]. 中国医药导报, 2019,16(32):30-33.
	Jing JF, Gao JN, Li D, et al. Progress of research on financial toxicity of breast cancer[J]. China Med Her, 2019,16(32):30-33.
[25]	Moon Z, Hunter MS, Moss-Morris R, et al. Factors related to the experience of menopausal symptoms in women prescribed tamoxifen[J]. J Psychosom Obstet Gynaecol, 2017,38(3):226-235. DOI PMID
[26]	Nestoriuc Y, Von Blanckenburg P, Schuricht F, et al. Is it best to expect the worst? Influence of patients’ side-effect expectations on endocrine treatment outcome in a 2-year prospective clinical cohort study[J]. Ann Oncol, 2016,27(10):1909-1915. DOI URL